National and Kapodistrian University of Athens
Διερεύνηση των παθογενετικών μηχανισμών της πνευμονικής ίνωσης και του καρκίνου του πνεύμονα
Abstract
dc:descriptionIdiopathic pulmonary fibrosis (IPF) is a rare fatal disease of interstitial pneumonia of unknown etiology. The disease is characterized by increased proliferation of fibroblasts and increased collagen deposition in the lungs, which is normally produced in wound healing. The pathogenesis remains unknown, however risk factors (genetic and environmental) appear to cause lung damage, resulting in the activation of fibroblasts, their differentiation into myοfibroblasts, which produce an excessive amount of extracellular matrix. 2015, the FDA approved 2 drugs for the treatment of pulmonary fibrosis, however so far they do not seem to completely cure, reducing mortality, but improve the living conditions of patients.The animal model of bleomycin is used to analyze the characteristics of IPF, which represents the basic characteristics of the disease in animals. In the context of research into new potential target molecules that could contribute to the progression of the disease, a study was initially conducted in which an attempt was made to optimize the bleomycin model. Two routes of administration (intratracheal and oropharyngeal) and different doses of bleomycin were tested and directly compared for the first time, using a variety of assays, including in vivo measurements of pulmonary function that are highly relevant to the clinical picture. Our results suggest that the OA route can be used as a safe and effective alternative route of BLM administration, allowing researchers to produce easily reproducible fibrotic profiles in conjunction with a beneficial safety profile that avoids invasive surgical procedures, results of higher doses of BLM. In addition, the low concentrations of BLM that used will allow drug testing in much better shaped animals without compromising a solid fibrotic profile. The etiology remains unknown but risk factors are genetic as well as environmental factors, among them epigenetic modifications. All enzymes that induce epigenetic modifications in the context of pulmonary fibromycin fibrosis were studied at the mRNA expression level. The study then focused on the Smyd3-histone methyltransferase gene, whose expression is increased in the fibrotic lungs. The bleomycin model was then applied to Smyd3 transgenic knock-out mice as well as control mice. However, the phenotype of the disease did not appear to change when the gene was silenced in all tissues.In addition, the Map3k8 gene and its role in pulmonary fibrosis were studied and it was found that MAP3K8 plays a central role in the pathogenesis of IPF involving the regulation of CoGE-2-induced PGE2 production in the lung.The genes whose expression changes in IPF and PF were then searched. From the data that emerged we focused on genes related to the extracellular matrix and more specifically the SH3PXD2A gene. The SH3PXD2A gene encodes the TKS5 adapter protein, whose main role is to promote signaling by binding to various other proteins, which can thus interact with each other. This protein is also involved in the formation of the actin cytoskeleton, which is a primary event in the differentiation of lung fibroblasts into myofibroblasts, as well as in the ability of certain cancer cells to penetrate. In addition, TKS5 contributes to extracellular matrix homeostasis through its interaction with Adams metalloproteases.Thus, for the first time, the increase of mRNA in but also of the protein of the SH3PXD2A / TKS5 gene was confirmed in fibroblasts after the induction of tgf-β1 in the form of rossettes. The protein cortactin, an adhesome molecule, a well-known indicator of podosomes, was also identified. Podosomes are known to induce the expression of metalloproteinases through the rossettes they create and induce the degradation of the extracellular matrix with the aim of migrating cells. In pulmonary fibrosis the migrating cells are myofibroblasts with the aim of enhancing the fibrotic pattern.For these reasons, after the genetic creation of Tks5-conditional knock out and heterozygous mice, the fibrotic model was applied to them either in vitro or in vivo. For further investigation and the possible effect of genetic targeting on the fibrotic phenotype, bleomycin-induced pulmonary fibrosis was performed in knock-out heterozygous mice (Sh3pxd2atm1b) and the corresponding control mice. Genetic targeting has led to an improvement in the fibrotic phenotype in all protocols compared to wild-type mice, in terms of inflammation, collagen concentration, assessment of respiratory function. This result could be explained by the fact that Tks5 after induction of tgf-β1 is a key component of podosomes and promotes ECM degradation through MmP9 and enhances migration. Thus, silencing the gene could inhibit the migration of myofibroblasts, thereby improving pulmonary fibrosis.In conclusion, half-genetic silencing of the Tks5 gene has led to an improvement in the experimental model of bleomycin, however more studies are needed on the mechanism leading to these results. Of course, the study of podosomes in pulmonary fibrosis in both humans and mice needs further investigation and other complementary experiments to clarify and prove the role of podosomes. Finally, this study is more interesting as podosomes play an important role in lung cancer and fibrosis is known to be a risk factor for lung cancer.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Barmpagianni, Ilianna-Maria
- Μπαρμπαγιάννη, Ηλιάννα-Μαρία
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/50815